NHI.no
Annonse
Informasjon, tilstand

Psoriasis, en oversikt

Psoriasis er en betennelse i huden som kan gi utslett over store deler av kroppen. 2-3 prosent av befolkningen er rammet av sykdommen, som til en viss grad kan være arvelig.

Psoriasis kan gi utslett over alt på huden, inkludert hodebunn og ører.

Sist oppdatert:

27. mars 2024

Vil du vite mer

Dette dokumentet er basert på det profesjonelle dokumentet Psoriasis . Referanselisten for dette dokumentet vises nedenfor

  1. Griffiths CEM, Armstrong AW, Gudjonsson JE, Barker JNWN. Psoriasis. Lancet. 2021;397(10281):1301-1315. PubMed
  2. Weigle N, McBane S. Psoriasis. Am Fam Physician 2013; 87: 626-33. PubMed
  3. Coates LC, Moverley AR, McParland L, et al. Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a UK multicentre, open-label, randomised controlled trial. Lancet. 2015;386(10012):2489-98. PubMed
  4. Griffiths CEM, Armstrong AW, Gudjonsson JE,et al.Lancet. 2021 Apr 3;397(10281):1301-1315. PMID: 33812489. pubmed.ncbi.nlm.nih.gov
  5. Psoriasis-og eksemforbundet: Psoriasis, siden lest 24.03.24 cms.legehandboka.no
  6. Armstrong AW, Mehta MD, Schupp CW,et al. Psoriasis Prevalence in Adults in the United States. JAMA Dermatol. 2021 Jun 30. PMID: 34190957.
  7. Patrisi R, Symmons DP, Griffiths CE, et al. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol 2013; 133: 377-85. PubMed
  8. Hoff M, Malm Gulati A, Romundstad PR, et al. Prevalence and incidence rates of psoriatic arthritis in central Norway: data from the Nord-Trøndelag Health Study (HUNT). Ann Rheum Dis 2015; 74: 60–64.
  9. Alinaghi F, Calov M, Kristensen LE, et al. Prevalence of psoriatic arthritis in patients with psoriasis: A systematic review and meta-analysis of observational and clinical studies. J Am Acad Dermatol. 2019 Jan;80(1):251-265.e19. PMID: 29928910. PubMed
  10. Griffiths CEM, Barker JNWN. Pathogenesis and clinical features of psoriasis. Lancet 2007; 370: 263-71. PubMed
  11. Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med. 2009;361(5):496-509. PubMed
  12. Zhao SS, Yiu ZZN, Barton A, Bowes J. Association of Lipid-Lowering Drugs With Risk of Psoriasis A Mendelian Randomization Study. JAMA Dermatol 2023. pmid:36696131 PubMed
  13. Meffert J. Psoriasis. Medscape, last updated Apr 06, 2017. emedicine.medscape.com
  14. Chen T-L, Lee L-L, Huang H-K, et al. Association of Psoriasis With Incident Venous Thromboembolism and Peripheral Vascular Disease A Systematic Review and Meta-analysis. JAMA Dermatol 2021. pmid:34851364 PubMed
  15. Horn EJ, Fox KM, Patel V, et al. Are patients with psoriasis undertreated? Results of National Psoriasis Foundation survey. J Am Acad Dermatol. 2007;57(6):957-62. PubMed
  16. Chiricozzi A. Psoriasis. BMJ Best Practice, last updated 30 Oct 2020.
  17. Philipp S, Wolk K, Kreutzer S, et al. The evaluation of psoriasis therapy with biologics leads to a revision of the current view of the pathogenesis of this disorder. Expert Opin Ther Targets 2006;10:817-831. PubMed
  18. Burden-Teh E, Phillips RC, Thomas KS et al. A systematic review of diagnostic criteria for psoriasis in adults and children: evidence from studies with a primary aim to develop or validate diagnostic criteria. Br J Dermatol 2018; 178:1035–43.
  19. Ryan C, Menter A. Psoriasis and cardiovascular disorders. G Ital Dermatol Venereol 2012; 147: 189-202. pmid:22481581 PubMed
  20. Langenbruch A, Radtke MA, Krensel M, Jacobi A, Reich K, Augustin M. Nail involvement as a predictor of concomitant psoriatic arthritis in patients with psoriasis. Br J Dermatol. 2014 Nov. 171(5):1123-8.
  21. European Dermatology Forum. Living EuroGuiDerm Guideline for the systemic treatment of psoriasis vulgaris. Last updated 07/2020. www.edf.one
  22. Smith CH, Jabbar-Lopez ZK, Yiu ZZ, et al. British Association of Dermatologists guidelines for biologic therapy for psoriasis 2017. Br J Dermatol. 2017;177(3):628-36. PubMed
  23. Store medisinske leksikon, hudlege Tor Langeland, Koebnerfenomen, sist oppdatert 11.11.2022, siden lest 25.03.24 sml.snl.no
  24. Ko SH, Chi CC, Yeh ML, et al. Lifestyle changes for treating psoriasis. Cochrane Database Syst Rev. 2019 Jul 16;7(7):CD011972. PMID: 31309536. PubMed
  25. Schlager JG, Rosumeck S, Werner RN, Jacobs A, Schmitt J, Schlager C, Nast A. Topical treatments for scalp psoriasis. Cochrane Database of Systematic Reviews 2016, Issue 2. Art. No.: CD009687. DOI: 10.1002/14651858.CD009687.pub2. DOI
  26. Samarasekera EJ, Sawyer L, Wonderling D, et al. Topical therapies for the treatment of plaque psoriasis: systematic review and network meta-analyses. British Journal of Dermatology 2013; 168: 954-67. doi:10.1111/bjd.12276 DOI
  27. Wang C, Lin A. Efficacy of topical calcineurin inhibitors in psoriasis. J Cutan Med Surg. 2014;18(1):8-14. PubMed
  28. Lapolla W, Yentzer BA, Bagel J, et al. A review of phototherapy protocols for psoriasis treatment. J Am Acad Dermatol. 2011;64:936-949. PubMed
  29. Jabbar-Lopez ZK, Wu KC, Reynolds NJ. Newer agents for psoriasis in adults. BMJ. 2014;349:g4026. doi: 10.1136/bmj.g4026. DOI
  30. Olav Sundnes: Veiledende anbefalinger for systemisk behandling av psoriasis vulgaris, versjon 2, mars 2023, siden lest 23.03.24 www.legeforeningen.no
  31. Montaudie H, Sbidian E, Paul C, et al. Methotrexate in psoriasis: a systematic review of treatment modalities, incidence, risk factors and monitoring of liver toxicity. J Europ Acad Dermatol Venereol. 2011;25(suppl 2):12-18.
  32. Maza A, Montaudie H, Sbidian E, et al. Oral cyclosporin in psoriasis: a systematic review on treatment modalities, risk of kidney toxicity and evidence for use in non-plaque psoriasis. J Euro Acad Dermatol Venereol. 2011;25(suppl 2):19-27. PMID: 21388455. PubMed
  33. Sbidian E, Chaimani A, Afach S, et al. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta‐analysis. Cochrane Database of Systematic Reviews 2020, Issue 1. Art. No.: CD011535. The Cochrane Library
  34. Spes i hudsykdommer: Olav Sundnes m.fler: Veiledende anbefalinger for systemisk behandling av psoriasis vulgaris, sept. 2021, siden lest 26.03.24 www.legeforeningen.no
  35. Meng Y, Dongmei L, Yanbin P, et al. Systematic review and meta-analysis of ustekinumab for moderate to severe psoriasis. Clin Exp Dermatol. 2014;39(6):696-707. doi: 10.1111/ced.12390.
  36. Griffiths CE, Strober BE, van de Kerkhof P, et al. Comparison of ustekinumab and etarnecept for moderate- to severe psoriasis. N Engl J Med 2010; 362: 118-28. New England Journal of Medicine
  37. Langley RG, Elewski BE, Lebwohl MN, et al. Secukinumab in plaque psoriasis--results of two phase 3 trials. N Engl J Med. 2014;371:326-338. PubMed
  38. Hammadi AA. Psoriatic arthritis. Medscape, last updated Dec 11, 2014.
  39. Leisner MZ, Riis JL, Schwartz BS et al. Psoriasis and Risk of Mental Disorders in Denmark. JAMA Dermatol 2019.0039 pmid:31066861 PubMed
  40. Mason AR, Mason J, Cork M, et al. Topical treatments for chronic plaque psoriasis. Cochrane Database Syst Rev 2013; :CD005028. Cochrane (DOI)
  41. Dupire G, Droitcourt C, Hughes C, Le Cleach L. Antistreptococcal interventions for guttate and chronic plaque psoriasis. Cochrane Database of Systematic Reviews 2019, Issue 3. Art. No.: CD011571. DOI: 10.1002/14651858.CD011571.pub2. DOI
  42. Pouplard C, Brenaut E, Horreau C, et al. Risk of cancer in psoriasis: a systematic review and meta-analysis of epidemiological studies. J Eur Acad Dermatol Venereol. 2013;27(suppl 3):36-46. PMID: 23845151 PubMed
  43. Trafford AM, Parisi R, Kontopantelis E, et al. Association of Psoriasis With the Risk of Developing or Dying of Cancer A Systematic Review and Meta-analysis. JAMA Dermatol 2019. pmid:31617868 PubMed
  44. Ahlehoff O, Gislason GH, Charlot M et al. Psoriasis is associated with clinically significant cardiovascular risk: a Danish nationwide cohort study. J Intern Med 2011; 270: 147-57. PubMed
  45. Ahlehoff O, Skov L, Gislason G, et al. Cardiovascular disease event rates in patients with severe psoriasis treated with systemic anti-inflammatory drugs: a Danish real-world cohort study. J Intern Med 2012. doi:10.1111/j.1365-2796.2012.02593.x DOI
  46. Li X, Andersen KM, Chang H-Y, et al. Comparative risk of serious infections among real-world users of biologics for psoriasis or psoriatic arthritis. Ann Rheum Dis 2019. pmid:31672774 PubMed
  47. Crowley JJ, Weinberg JM, Wu JJ et al. Treatment of Nail Psoriasis. JAMA Dermatol 2015; 151(1): 87-94. pmid:25471223 PubMed
  48. Ibrahim G, Waxman R, Helliwell PS. The prevalence of psoriatic arthritis in people with psoriasis. Arthritis Rheum 2009; 61: 1373-8. pmid:19790120 PubMed
  49. Feldman SR. Epidemiology, clinical manifestations, and diagnosis of psoriasis. UpToDate, last updated Dec 30, 2019. UpToDate
  50. Sterry W, Ortonne J-P, Kirkham B. Comparison of two etanercept regimens for treatment of psoriasis and psoritaic arthritis: PRESTA randomised double blind multicentre trial. BMJ 2010; 340: c147. BMJ (DOI)
  51. Paller AS, Siegfried EC, Langley RG, et al, for the Etanercept Pediatric Psoriasis Study Group. Etanercept treatment for children and adolescents with plaque psoriasis. N Engl J Med 2008; 358: 241-51. New England Journal of Medicine
Annonse
Annonse